SeaSpine® Announces Limited Commercial Launch of Explorer™ TO Expandable Interbody Device
CARLSBAD, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of the Explorer™ TO System.
Explorer TO represents SeaSpine’s first new product offering since 2017 in the estimated $400 million expandable interbody market. The system provides an innovative and elegant posterior interbody solution that offers both parallel and lordotic expansion options to fit patient anatomy, as well as surgeon preference.
“This new expandable design not only provides me with the clinical options to achieve my goals as a surgeon but gives me one instrumentation system for two different styles of implants,” said Dr. Azam Basheer from Henry Ford Hospital. “This doubles the number of options I have in the OR without doubling the number of instruments required.”
The system’s innovative implant provides a low-profile design for insertion with expansion versatility achieving up to 16mm in height for both parallel (from 7mm) and lordotic (from 10mm) options. Both implant choices connect to the same inserter, allowing spine surgeons to more efficiently address each patient’s varying anatomy, as well as sagittal alignment goals, during the procedure, without having to change instrumentation or technique.
“Explorer TO is impressive”, said Dr. Ben Chen from MultiCare Good Samaritan Hospital. “Having an expandable cage allowed me to address a narrow opening. However, I was able to achieve my decompression goals for what would normally have needed a larger implant. Explorer TO’s instrumentation is streamlined and intuitive. The ability to post pack bone graft through the inserter eliminates an extra step and saves time. The variable options of height and lordotic expansion provide me the confidence that I will be able to treat multiple pathologies among multiple patient anatomies moving forward.”
“Explorer TO gives us a new product offering in a market segment in which we previously did not meaningfully compete,” said Dennis Cirino, Senior Vice President, Global Spinal Systems. “Its thoughtful design is intended to improve surgical outcomes and capture economic efficiencies, with instrumentation that works across both parallel and lordotic cage options and implants designed with open channels to allow for reliable bone graft delivery post-implantation. The implant’s bulleted nose allows for a small footprint to access narrow anatomy, which then expands to meet the decompression and grafting goals for the multitude of anatomical challenges facing surgeons. The benefit of gaining greater access to this growing market segment provides SeaSpine and its expanding distribution channel a new opportunity to compete and grow with industry leading technology.”
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of Orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s Orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both Orthobiologics sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the Explorer TO system’s implant design and ability to connect to the same inserter and ability to allow spine surgeons to more efficiently address patient anatomy and sagittal alignment goals during a procedure without changing instrumentation or technique; the ability of the design of Explorer TO to improve surgical outcomes and capture economic efficiencies, whether with instrumentation that works across both parallel and lordotic cage options or implants designed for open channels to allow for reliable bone graft delivery post-implantation; and the ability of Explorer TO provide SeaSpine greater access to the expandable interbody market segment; and growing market segment provides SeaSpine and its expanding distribution channel a new opportunity to compete and grow with industry leading technology. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of substantial clinical validation of products following limited commercial (or “alpha”) launch; unexpected delay, including as a result of developing and supporting the launch of new products, including the fact that newly launched products may require substantial additional development activities, which could introduce further delay, or as a result of obtaining regulatory clearances; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact